Hip bursitis vs. arthritis: How to tell the difference
Fitness for longevity: Which type matters most?
Ministrokes linked to elevated risk of dementia
Continuous glucose monitors benefit people who don't need insulin
CoQ10: Should you take this popular supplement if you're on a statin?
Microplastics: A hidden health threat?
Oat vs. dairy milk: Nutrition, benefits, and downsides
What is tempeh? Benefits, nutrition, and how to use it
Healing after food poisoning
Whole grains may improve several heart risk factors at once
Adam S. Cheifetz, MD
Contributor
Dr. Adam Cheifetz is director of the center for inflammatory bowel disease and medical director of infusion services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School. He is a well-recognized leader in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. He is involved in multiple research projects relating to IBD, and has published over 200 articles and chapters on the subject.
His research currently focuses on therapeutic drug monitoring and optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care.
Hip bursitis vs. arthritis: How to tell the difference
Fitness for longevity: Which type matters most?
Ministrokes linked to elevated risk of dementia
Continuous glucose monitors benefit people who don't need insulin
CoQ10: Should you take this popular supplement if you're on a statin?
Microplastics: A hidden health threat?
Oat vs. dairy milk: Nutrition, benefits, and downsides
What is tempeh? Benefits, nutrition, and how to use it
Healing after food poisoning
Whole grains may improve several heart risk factors at once
